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Image-guided neural activity manipulation with
a paramagnetic drug
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Targeted manipulations of neural activity are essential approaches in neuroscience and
neurology, but monitoring such procedures in the living brain remains a signiﬁcant challenge.
Here we introduce a paramagnetic analog of the drug muscimol that enables targeted neural
inactivation to be performed with feedback from magnetic resonance imaging. We validate
pharmacological properties of the compound in vitro, and show that its distribution in vivo
reliably predicts perturbations to brain activity.
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Neuromodulation methods are widely used for perturba-tions of neural activity in both basic science and clinicalpractice, but monitoring the time course and spatial
extent of modulatory tools in living subjects is challenging. Even
with modern optogenetic and chemogenetic approaches1,2,
measurement of actuator expression proﬁles is usually only
possible postmortem, and the efﬁcacy of these tools depends on
light or drug level proﬁles that are rarely characterized. Tradi-
tional neuropharmacological perturbations are easier to apply in
many species, but are also hard to monitor in vivo. Although
ﬂuorescent drug conjugates can be mapped histologically after
death3, the resulting proﬁles may not reﬂect the distribution or
dose that produced experimental neural activity perturbations
of interest. Radiolabeled drugs can be mapped using nuclear
imaging methods in living subjects4, but the tomographic
instrumentation applied in such approaches typically provides
poor spatiotemporal resolution, and synthesis and handling of the
radiopharmaceuticals themselves is complex.
Here we describe an approach to image-guided manipulation
of brain activity based on paramagnetic drugs that can be
visualized noninvasively by magnetic resonance imaging (MRI).
We apply the principle to muscimol, an agonist of γ-
aminobutyric acid (GABA) A receptors that is widely used for
targeted inactivation of neural structures, and that has previously
been applied as a ﬂuorescent conjugate for postmortem histolo-
gical imaging5. By chemically conjugating muscimol to a gado-
linium chelate, we sought to create a paramagnetic muscimol
analog (ParaMus) whose distribution could be imaged in real
time in vivo, while offering pharmacological properties compar-
able to muscimol itself.
Results
Synthesis and characterization of ParaMus. The synthesis of
ParaMus is diagrammed in Fig. 1a. The metal-free precursor to
ParaMus (6) is prepared through cross-coupling of muscimol with
the gadolinium binding ligand 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA), using a bifunctional triethylene
glycol linker. ParaMus (7) is then formed by reacting 6 with excess
of GdCl3 at pH 5. Integrity and purity of the ﬁnal compound is
indicated by mass spectrometry and liquid chromatography
(Supplementary Fig. 1). The MRI potency of ParaMus is reﬂected
by the slope of its effect on the reciprocal of the longitudinal
relaxation time (T1) versus concentration, known as longitudinal
relaxivity (r1). MRI measurements at 7 T and room temperature
indicate that the r1 of ParaMus is 5.0 ± 0.2mM−1 s−1 (error mar-
gins reﬂect SEM with n= 3, unless otherwise noted); this value is
somewhat larger than the r1 value of 3.6 ± 0.3mM−1 s−1 for
gadoteridol6, a contrast agent that approximates the Gd-DOTA
moiety of ParaMus, and indicates that conjugation to muscimol
does not compromise contrast-inducing properties of the gadoli-
nium complex (Supplementary Fig. 2). Like Gd-DOTA, ParaMus
also displays a weak transverse relaxivity of 7.3 ± 0.6 mM−1 s−1
(Supplementary Fig. 3), which is unlikely to substantially alter
image contrast except at high concentrations.
To assess the efﬁcacy of ParaMus as an inhibitor of neuronal
excitability, we examined its pharmacological activity in vitro. We
subjected primary rat cortical neurons to intracellular current
clamp (Fig. 1b), and measured current thresholds for action
potential initiation under test and control conditions (Fig. 1c, d).
We found that untreated neurons exhibit a current threshold of
0.9 ± 0.2 nA (n= 4), compared with 2.1 ± 0.6 nA following bath
application of 10 µM ParaMus (n= 4). ParaMus also causes a
decrease of 77 ± 17% in input resistance. Neurons treated with
10 µM muscimol also display an increase in current threshold,
from 0.6 ± 0.1 to 1.4 ± 0.2 nA (n= 2), as well as a 71 ± 6%
decrease in input resistance, similar to ParaMus. By contrast,
gadoteridol elicits virtually no change in current threshold or
input resistance when tested in the same assay. This indicates that
the pharmacological effects of ParaMus arise from its muscimol
component.
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Fig. 1 Synthesis and pharmacological characterization of ParaMus. a Chemical synthesis of ParaMus (7): (i) HOOC-PEG3-NHBoc, EDC/NHS, MOPS
(100mM, pH 5.5), (ii) TFA/DCM (80:20), (iii) DOTA-NHS, MOPS (25mM, KCl 100mM, pH 8), (iv) GdCl3, H2O, pH 5.5. b Setup for intracellular
recording of primary rat cortical neurons (scale bar= 10 µm). c Representative current-clamp recordings in response to injection of 0.1-0.5 nA current
injection in the presence of vehicle, 10 µM muscimol, 10 µM ParaMus, and 10 µM gadoteridol. Scale bars, horizontal= 20ms, vertical= 10mV. d Current
thresholds for action potential generation before (−) and after (+) application of muscimol, ParaMus, or gadoteridol. Paired measurements are shown for
two (muscimol), four (ParaMus), or three (gadoteridol) independent experiments.
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Image-guided neural inactivation using ParaMus in vivo. To
demonstrate image-guided manipulation of a neural system
in vivo, we examined the ability of ParaMus to perturb brain
responses to a sensory stimulus in anesthetized rats. We used
functional MRI (fMRI) contrast to monitor brain-wide responses
to electrical stimulation of the forepaw7 before, during, and after
delivery of ParaMus to the ventral posterolateral nucleus of the
thalamus (VPL), a relay point in the transmission of somato-
sensory input from the body to the cortex. The distribution of
ParaMus infused via a cannula targeted to VPL could be visua-
lized by T1-weighted MRI (Fig. 2a). Before this treatment, fore-
paw stimulation produced strong fMRI responses in the forelimb
ﬁeld of primary somatosensory cortex (S1FL), and weak
responses in secondary somatosensory cortex (S2). After infusion
of 1.5 µL ParaMus (1 mM) into the VPL region, responses were
sharply reduced, as discernable from both activity maps (Fig. 2b)
and response time courses (Fig. 2c). Group results (Fig. 2d, e)
show that consistent decreases in the S1FL response to forepaw
stimulation can be observed following VPL-targeted ParaMus
treatment (n= 5), but not following control treatment with
gadoteridol (n= 4). Mean response amplitudes are 69 ± 22%
lower after ParaMus (signiﬁcant with paired t-test p= 0.04, n=
5), but an average of only 3 ± 43% lower after gadoteridol (paired
t-test p= 0.5, n= 4). These results indicate efﬁcacy and speciﬁcity
of ParaMus-dependent neural inactivation consistent with the
neurophysiology of the somatosensory system.
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Fig. 2 Image-guided manipulation of somatosensory responses in the rat brain. a Top: Coronal brain schematic12 at bregma= –2.8 mm, showing the
location of VPL (red) bordered on the lateral side by the internal capsule (IC). Bottom: a corresponding T1-weighted (T1w) coronal image showing contrast
enhancement in the VPL region following ParaMus infusion. Hypointense white matter IC signal denoted by arrowhead. b Forepaw stimulation-induced
fMRI responses, in units of percent signal change (%SC), in a single animal before (top) and after (bottom) the ParaMus infusion shown in a. S1FL and S2
regions labeled; bregma coordinates in yellow. c Time course of fMRI signal in the S1FL region pre- (gray) and post-infusion (red), corresponding to data in
b; stimulation blocks denoted by blue rectangles. d Change in fMRI response amplitudes (ΔRA), relative to pretreatment responses, after VPL-targeted
ParaMus infusion (top, n= 5) or control infusion with gadoteridol (bottom, n= 4). eMean relative peristimulus response time courses associated with the
maps in d, pre- and post-treatment with ParaMus (top) or gadoteridol (bottom). Shading denotes SEM over ﬁve animals (top) or four animals (bottom).
f Proﬁle of mean relative T1-weighted MRI signal changes following ParaMus infusion in ﬁve animals. Control infusions lacking contrast agent produced no
notable contrast enhancement. g A failed ParaMus infusion results in no enhancement in the posttreatment condition (left). Correspondingly, there is no
decrease in fMRI response to forepaw stimulation after treatment (right); error bars denote SEM of responses over 10 stimulus cycles in a single animal.
h Premature infusion of ParaMus is easily detectable by comparing pre- and post-treatment T1-weighted images. i Anomalous spatial distributions of
ParaMus are recognized in images of two separate animals in the postinfusion condition.
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The quintessential functionality afforded by ParaMus is an
ability to relate differences in neuromodulator infusion proﬁles to
resulting neurophysiological outcomes. In the experiments of
Fig. 2d, e, ParaMus infusion covered a distribution of areas in and
around VPL (Fig. 2f and Supplementary Fig. 4). Variations in the
infusion proﬁle among individuals could be detected by T1-
weighted imaging, revealing the extent to which apparently
equivalent injection procedures lead to different results. For
instance, a failed infusion could be detected by the absence of T1
enhancement, as well as corresponding fMRI response changes
(Fig. 2g). Premature infusion of ParaMus could be detected as T1
contrast or relaxation changes prior to purposeful injection
(Fig. 2h and Supplementary Fig. 5). Anomalous infusion proﬁles
arising from subtle differences in cannula placement or convec-
tion dynamics could also be recognized (Fig. 2i). T1-weighted
MRI readouts therefore provide instant feedback on the
characteristics of neuromodulatory drug delivery, with the
potential to guide experimental strategies. Quantitative analysis
of ParaMus-mediated T1 changes and corresponding effects in
fMRI reveals a signiﬁcant (correlation coefﬁcient= 0.70, p= 0.04,
n= 9) and approximately linear relationship between the extent
of fMRI responses in S1FL and the percentage of sensory
thalamus infused with ParaMus (Supplementary Fig. 6).
Another key capability ParaMus provides is the possibility of
relating drug distribution proﬁles at multiple time points to
responses observed during and after infusion. In a representative
animal, a decrease in fMRI responses to forepaw stimulation can
be detected progressively throughout ParaMus infusion, followed
by a partial recovery as the drug begins to wash out (Fig. 3a).
Evaluation of T1 relaxation rate time courses in such experiments
also enables in vivo estimation of the half-life for elimination of
ParaMus from the brain (Fig. 3b and Supplementary Fig. 7), a
value of ~30 min. Postmortem analysis of brain tissue after an
imaging experiment permits identiﬁcation of ParaMus by mass
spectrometry and reveals that the contrast agent remains intact
during the experimental period (Supplementary Fig. 8).
Discussion
These results demonstrate that ParaMus combines the pharma-
cological properties of muscimol with the MRI properties of
commercial contrast agents, enabling imaging-based assessment
and control over neural manipulations in the living brain. The
reagent is straightforward to produce and apply, and could
immediately be used in a range of biomedical contexts and in
species ranging from rodents to primates, possibly including
human subjects. In addition to fMRI responses like those exam-
ined here, other physiological and behavioral measures could also
be investigated in conjunction with ParaMus-mediated pertur-
bations, as long as MRI mapping of the drug distribution is
performed soon before or after the relevant experiments. Non-
MRI activity measurements are most feasible in the immediate
vicinity of ParaMus infusion, where fMRI signal might be dis-
torted by the contrast agent’s magnetic susceptibility. The closest
alternative to ParaMus-based procedures introduced here is
afforded by mixing muscimol with conventional MRI contrast
agents like gadoteridol8, but the properties of such admixtures are
considerably inferior. Muscimol and gadoteridol differ in mole-
cular weight by a factor of ﬁve, and while muscimol is positively
charged at pH 7, gadoteridol is neutral. Diffusion, molecular
adhesion, cell uptake, and pharmacokinetics of the two com-
pounds are likely to differ substantially, raising interpretive
questions that are avoided when using ParaMus.
In future work, the idea of conjugating paramagnetic moieties
to neuromodulatory agents could be extended to create additional
MRI-detectable drugs. Construction of ParaMus exploits the fact
that modiﬁcation of the muscimol amine does not compromise
pharmacological activity, but additional neurotransmitter recep-
tor ligands also possess sites where modiﬁcation is possible
without abrogating receptor afﬁnity9–11. A toolkit of imageable
drugs could potentially be multiplexed by attaching different
types of contrast agent—for instance employing T1 vs. transverse
relaxation (T2) or chemical exchange saturation transfer contrast-
inducing moieties—to different neuromodulatory substances. The
approach presented here may therefore promote an unprece-
dented level of informed, multimodal control over neural func-
tion in deep tissue.
Methods
Reagents and general chemical methods. All solvents were of reagent grade and
all other materials were purchased and used as received. Chemicals were procured
from Sigma Aldrich (St. Louis, MO) unless otherwise noted. Compound 5 was
procured from Macrocyclics (Plano, TX). Silica gel (230-400 mesh, VWR, Radnor,
PA) and octadecyl-functionalized silica gel (RP-18, Waters, Milford, MA) were
used for column chromatography. Analytical thin-layer chromatography was
performed by using Merck 60 F254 silica gel (precoated aluminum sheets, 0.25 mm
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Fig. 3 Time course of ParaMus-induced T1 contrast and fMRI response changes. a Maps showing infusion of contrast agent (top, bregma= –2.8 mm)
and fMRI responses (bottom, bregma+ 0.8mm) as a function of time in the subject of Fig. 2b. Data are shown before (Pre) and after ParaMus infusion, as
indicated by time points (t) in minutes shown below the images. The infusion maps display the change in T1-weighted signal (ΔT1w) due to ParaMus
infusion, in units of percent signal change (%SC) compared with preinfusion contrast, overlaid on an anatomical image. The fMRI activation maps indicate
mean response amplitudes induced by forepaw stimulation in 8.4-min trials beginning at each of the designated time points. Note the slight recovery of the
S1FL response peak at the 120min time point (arrowhead), after ParaMus contrast has largely dissipated, a result replicated also in a second animal. A
small amount of ParaMus leakage is also detectable as ΔT1w hyperintensity around the needle in the Pre image. b Washout of ParaMus following infusion
into brain, as reﬂected by the normalized change in T1 relaxation rate (R1) with respect to preinfusion conditions averaged over sensory thalamus. Values
indicate mean and SEM (error bars) of data from two animals. The data are ﬁt by an exponential decay curve (shown) with half-life 34min.
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thick). Reverse phase preparative high-performance liquid chromatography
(HPLC) traces were recorded at 298 K using a Waters (Milford, MA) HPLC system
equipped with a semi-preparative C18 column. A gradient elution with a solvent
system composed of water/acetonitrile with 0.1% triﬂuoroacetic acid (TFA) was
applied for a total run time of 33 min.
Mass spectrometry. Both standard and high-resolution electrospray mass spec-
trometry were recorded on an Agilent Technologies (Santa Clara, CA) HP
8453 spectrometer, operating in positive or negative ion mode as stated, with
MeOH as the carrier solvent. Matrix-assisted laser desorption ionization time of
ﬂight (MALDI-TOF) mass spectra were recorded on a Bruker Instruments
(Ettlingen, Germany) MicroFlex instrument with α-cyano-4-hydroxycinnamic acid
employed as the matrix and 50/50 water/acetonitrile+ 0.1% TFA used to prepare
all samples.
Elemental analysis. Absolute concentrations of ﬁnal puriﬁed complexes for
in vitro and in vivo studies were calculated by gadolinium content using inductively
coupled plasma mass spectrometry on an Agilent 7900 ICP-MS instrument.
Complexes were digested in concentrated nitric acid at 70 °C for 2 h, before being
diluted into 2% nitric acid at a working gadolinium concentration of 10–100 ppb.
Gadolinium concentration was calibrated with nine data points across the range of
1–500 ppb using known stock concentrations. Overall, 10 ppb erbium was used in
all samples as an internal standard. Each sample was prepared in triplicate and each
data point was measured in duplicate.
NMR spectroscopy. 1H and 13C NMR spectra of each compound were recorded
in commercially available deuterated solvents on a Bruker Avance III DPX 400
(1H at 400MHz, 13C at 101MHz). All chemical shifts are given in ppm and
coupling constants are in Hz.
Synthetic methods. Further detailed information regarding the synthesis and
characterization of Paramus (7) and related compounds are reported in Supple-
mentary Methods.
In vitro MRI. MRI data were acquired in a 12 cm outer diameter birdcage transceiver
for imaging at room temperature in a 20 cm bore Bruker 7 T Avance III MRI scanner.
Samples at varying concentrations in 20mM 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid (HEPES) buffer, pH 7.4, were loaded into a 384-well clear
polystyrene plate (Thermo Fisher Scientiﬁc, Waltham, MA), which had been pre-cut
in half to optimally ﬁt the coil. Unused wells were ﬁlled with buffer. Overall, 2 mm
slices were imaged through the samples with a ﬁeld of view (FOV) of 5 × 5 cm and
data matrix of 256 × 256 points. Data for longitudinal (r1) and transverse (r2) relax-
ivity measurements were acquired using a multi-slice multi-echo pulse sequence (echo
time, TE= 12–360ms, repetition time, TR= 100, 200, 300, 400, 500, 600, 700, 800,
900, 1000, 1200, 1500, 3000, 5000ms). Custom routines written in MATLAB
(Mathworks, Natick, MA) were used to reconstruct the images and compute
relaxation time constants by ﬁtting image intensity data to exponential decay curves.
Relaxivity values were then computed from the slope of T1 and T2 relaxation rates
versus contrast agent concentration, as determined by ICP-MS. Values of r1= 5.0 ±
0.2mM−1 s−1 and r2= 7.3 ± 0.6mM−1 s−1 were obtained for ParaMus, where the
error margins represent SEM of n= 3 measurements.
Animals. All animal procedures were performed in strict compliance with US
Federal guidelines, with oversight by the MIT Committee on Animal Care. A total
of nine male Sprague-Dawley rats (300–400 g), purchased from Charles River
Laboratories (Wilmington, MA), were used for the in vivo data presented in this
paper. The animals were housed and maintained on a 12 h light/dark cycle with ad
libitum access to food and water. Sample sizes for animal experiments were chosen
to ensure reproducibility and quantify observed effects, rather than to guarantee
recognition of prespeciﬁed effect sizes with a given level of power. Experiments
were not randomized or blinded.
Electrophysiology. Cortical neurons from E18 Sprague-Dawley rat embryos were
kindly provided by the laboratory of Elly Nedivi (Picower Institute for Learning
and Memory). The cells were seeded at 1.5 × 105 cells per 18 mm on #1 round
coverslips coated with laminin (Life Technologies, Woburn, MA) and poly-D-
lysine (Sigma-Aldrich, St. Louis, MO). Prior to electrophysiological measurements,
cells were incubated in 2% B-27 supplement and 1% GlutaMAX (Thermo Fisher
Scientiﬁc) for seven days. Recordings were performed at room temperature from
neurons in extracellular solution containing 145 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 1 mM CaCl2, 5 mM HEPES, 5 mM glucose, 20 mM sucrose, 0.25 mg/L
phenol red, and 10 µM D-serine (all materials from Sigma-Aldrich). The pH of this
solution was adjusted to 7.4 with NaOH, and its osmolarity was adjusted to 315
mOsms with sucrose. Electrodes were pulled in two stages from borosilicate glass
capillaries (A-M systems, Sequim, WA) using a horizontal pipette puller (PD-97,
Sutter instruments, Novato, CA), resulting in resistances of 8–12MΩ when ﬁlled
with an internal solution containing 145 mM KCl, 10 mM HEPES, 5 mM adeno-
sine triphosphosphate, 0.2 mM guanosine triphosphate, and 10 mM ethylene
glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid, adjusted to pH 7.2 with
KOH. Whole-cell current-clamp recordings were performed using AxoClamp 1B
ampliﬁer (Axon Instruments, Union City, CA). Cell membrane potentials were
initially set to –60 mV, and voltage response to 50 ms current pulses of increasing
amplitude, in 0.1 nA steps, were used to assess action potential thresholds and
input resistances. To determine the effects of pharmacological agents, this proce-
dure was performed following bath application of 10 µM muscimol (Sigma-
Aldrich), 10 µM gadoteridol (Sigma-Aldrich), or 10 µM ParaMus.
Surgical methods. In preparation for imaging experiments with intracranially-
infused ParaMus or control agents, rats were implanted with infusion cannulae
targeting VPL. Animals were anaesthetized with 2% isoﬂurane, shaved, and
mounted in a rodent stereotaxic device (David Kopf Instruments, Tujunga, CA).
Heart rates and blood oxygenation levels were monitored by a pulse oximeter
(Nonin Medical, Plymouth, MN). Each rat was given a subcutaneous injection of
slow-release buprenorphine (MIT pharmacy) at a dose of 1 mg/kg for analgesia at
the beginning of surgery. The scalp was retracted and 28 G holes were drilled into
the skull 3.2 mm posterior and 3 mm lateral to bregma, unilaterally or bilaterally,
with coordinates based on a standard rat brain atlas12. Overall, 28 G cannula guides
(Plastics One, Roanoke, VA) designed to project 2 mm below the surface of the
skull were implanted and secured using C&B Metabond dental cement (Parkell,
Edgewood, NY). Small plastic head-posts were implanted to facilitate head ﬁxation
during the MRI experiments. Finally, 32 G dummy cannulae designed to ﬁt the
guide cannulae were inserted to protect the openings when not in use. Rats were
allowed to recover from surgery for at least three days before imaging.
In vivo MRI. Immediately prior to imaging experiments, cannula-implanted rats
were brieﬂy anesthetized using 3% isoﬂurane and maintained at 2% isoﬂurane
during preparation. Animals were intubated and ventilated, and an intraperitoneal
catheter was established for drug delivery. Animals were then placed onto a cradle
and secured in place via screws that attached to the implanted head-post. Isoﬂurane
was discontinued and intraperitoneal bolus doses of 0.1 mg/kg dexdomitor (MIT
pharmacy) and 1 mg/kg pancuronium (Sigma-Aldrich) were administered, fol-
lowed by continuous delivery of 0.2 mg/kg/h dexdomitor and 2 mg/kg/h pancur-
onium thereafter. Respiration, heart rate, and blood oxygen saturation were
monitored, and temperature was maintained with a circulating warm water pad
(Gaymar, Orchard Park, NY) for the remainder of the procedures. Overall, 32 G
internal cannula (Plastics One) preloaded with 1 mM ParaMus, 1 mM gadoteridol,
or saline vehicle were inserted at this time, targeting VPL via the previously
implanted guide cannulae. Internal cannulae extended 5–6 mm below the brain
surface. Animals were then inserted into the MRI scanner.
In vivo imaging was performed using a 9.4 T Biospec MRI scanner (Bruker)
scanner operating with a cross coil volume transmit, surface receive conﬁguration.
A rapid acquisition with refocused echoes (RARE) pulse sequence were used to
acquire T2-weighted anatomical images, with number of averages (NA)= 4, matrix
size= 256 × 192, FOV= 2.56 cm × 1.28 cm, slice thickness= 1 mm, TR= 5000 ms,
effective TE= 30 ms, and RARE factor= 8. To quantify the extent of ParaMus
infusion, T1-weighted RARE images were also acquired, using NA= 6, matrix size
= 128 × 64, FOV= 2.56 cm × 1.28 cm, slice thickness= 1 mm, TR= 252 ms, and
effective TE= 5 ms. For T1 mapping, data were acquired with additional TR values
of 429, 600, 900, 1000, 1500, 2000, 2500, and 3000 ms. For functional imaging,
echo-planar imaging (EPI) image series were acquired during alternating blocks of
forepaw stimulation and rest. EPI scan parameters were NA= 1, matrix size=
64 × 32, FOV= 2.56 cm × 1.28 cm, slice thickness= 1 mm, TR= 2000 ms, and
effective TE= 16 ms.
Forepaw stimulation itself was performed using 9Hz pulse trains with 1ms pulse
width and current of 3–6mA. Forepaw stimulation blocks were 10 s long, and were
delivered in ten cycles with 40 s rest periods in between. In two animals, forepaw
imaging trials were performed repeatedly, every 30min, along with T1 mapping to
determine the time course of ParaMus washout and corresponding changes in fMRI
responses. In seven animals, measurement of fMRI responses before vs. after ParaMus
infusion was performed in parallel with measurement of fMRI responses before vs.
after control treatment with saline or gadoteridol. In these cases, test and control
solutions were delivered via bilateral cannulae inserted in opposite hemispheres, and
corresponding contralateral forepaws were stimulated in each case. Four animals that
experienced suboptimal ParaMus targeting were excluded from the group data
quantifying the efﬁcacy of VPL ParaMus delivery (Fig. 2d), but were included in
Supplementary Fig. 6, which speciﬁcally relates variation in ParaMus delivery to
differences in the effects on fMRI responses.
MRI data analysis. Images were reconstructed using Paravision software (Bruker)
and further analyzed using custom routines implemented in MATLAB. Pre-
processing of functional imaging data was performed using the AFNI software
package (National Institute of Mental Health, Bethesda, MD)13. Steps included
motion correction using a rigid-body volume registration algorithm, spatial and
temporal smoothing, voxel-wise intensity normalization, and segmentation of
brain from nonbrain voxels. To coregister images into a uniform space, a reference
anatomical scan was ﬁrst manually aligned to a digitized version of a standard rat
atlas12. All other anatomical scans were then aligned to the reference image using a
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nine-parameter afﬁne transformation implemented in AFNI. Each animal’s EPI
scans were aligned to the corresponding coregistered anatomical scan. The time-
series data from the EPI scans were smoothed with a Gaussian spatial kernel of 1
mm full width at half-maximum prior to statistical analysis, and each voxel time
course was subsequently temporally smoothed using a sliding box window of
width 3.
Initial statistical analysis of preprocessed EPI scans was performed in AFNI.
Regression coefﬁcients for activation maps were computed by convolving the
electrical forepaw stimulus times with a hemodynamic response model. Six motion
correction parameters were included from each animal as nuisance regressors. Outlier
scans detected by median absolute deviation from time-series trends in each data set
were censored from the analysis.
Response amplitudes and t statistics for voxels that fell within the atlas-deﬁned
somatosensory cortex12 were used as input for further analysis of fMRI results in
MATLAB. To generate response maps such as Fig. 2b, the response in units of
percent signal change (%SC) was indicated for all voxels whose p value was below
an uncorrected signiﬁcance threshold of 0.05. To generate time courses in Fig. 2c,
responses were averaged over all voxels meeting the signiﬁcance criterion prior to
ParaMus infusion. To generate the difference maps in Fig. 2d, the percent signal
change estimated by general linear modeling to a stimulus regressor before
injection was subtracted from the percent signal change observed after injection on
a voxel-by-voxel basis. To compensate for variability in the pretreatment response
amplitudes among animals, difference maps from each animal were normalized to
the peak values observed before treatment and then averaged across the animals.
Thus, blue corresponding to a value of –1 indicates complete abrogation of the
response on average, as a result of treatment. The time courses of Fig. 2e were
computed by similarly normalizing each time course to the peak value observed in
the preinjection condition, followed by averaging over voxels in S1FL and then over
animals. Error margins reported in each case represent the standard error of the
mean over animals (n= 5 for ParaMus treatment and n= 4 for gadoteridol control
treatment).
Maps of contrast agent-dependent signal change in T1-weighted MRI scans,
such as Fig. 2f, were computed on by applying the formula %SC= 100 ×
(Spost – Spre)/Spre on a voxel-wise basis, where Spre and Spost are the signal amplitudes
observed before and after infusion, respectively. These maps were averaged over
animals (n= 5). Maps of T1 and R1 (= 1/T1) were computed by exponential ﬁtting
to T1-weighted data acquired at multiple TR values, as speciﬁed above. Values were
averaged across sensory thalamus (VPL and ventroposterior thalamus, a total of 40
voxels) to obtain reported means. Correspondence of ParaMus injection spread
and fMRI activation extent was examined by computing the percentage of sensory
thalamus ﬁlled during ParaMus infusion, and plotting this against the percent
change in the number of voxels showing signiﬁcant (F-test p < 0.05) stimulus-
dependent modulation after vs. before infusion.
Analysis of ParaMus in injected brain tissue. A rat was sacriﬁced and purfused
with NaCl solution (0.9%) ~1 h after ParaMus infusion as described above. The
collected brain sample was dounced in methanol (5 mL) for 5 min and centrifuged
at 3000 × g for 10 min. The supernatant was collected and the residue was dounced
again in methanol for 1 min and centrifuged for another 10 min at 3000 × g. This
procedure was repeated two further times. All collected methanol supernatant
fractions were pooled and ﬁltered through a 0.2 µm ﬁlter. The resulting clear
solution was concentrated to dryness under vacuum, dissolved in 500 µL deionized
water, and ﬁltered through a 3 kDa cutoff ﬁlter. The ﬁltrate was then concentrated
to 250 µL under vacuum and analyzed using an Agilent 6125B mass spectrometer
attached to an Agilent 1260 Inﬁnity LC system.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Scripts used for data analysis are available upon reasonable request.
Code availability
Raw MRI datasets generated during and/or analyzed during the current study are
available from the corresponding author on reasonable request.
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